Sinaptica Therapeutics, Inc
Sinaptica Therapeutics is a pioneering company developing personalized, non-invasive neuromodulation therapies for Alzheimer's Disease and other neurodegenerative conditions. Their mission is to significantly slow disease progression through innovative brain stimulation techniques, leveraging advanced neuroimaging, AI, and machine learning to tailor treatments to individual patients. With a focus on safety, efficacy, and cost-effectiveness, Sinaptica aims to transform the landscape of neurodegenerative disease management and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Patents
Systems and methods to enhance memory using non-invasive brain stimulation
US-12440695-B2
View DetailsSystems and methods for providing personalized targeted non-invasive stimulation to a brain network
US-11998740-B2
View Details
Systems and methods to enhance memory using non-invasive brain stimulation
US-12440695-B2
View DetailsSystems and methods for providing personalized targeted non-invasive stimulation to a brain network
US-11998740-B2
View DetailsProducts
Investigational personalized neuromodulation platform
An investigational noninvasive neuromodulation platform that integrates MRI-guided neuronavigation, stimulation hardware and concurrent electrophysiology with cloud-based algorithms to deliver individualized stimulation to targeted brain networks using an induction-plus-maintenance protocol. Intended for investigational use in clinical research.
Investigational personalized neuromodulation platform
An investigational noninvasive neuromodulation platform that integrates MRI-guided neuronavigation, stimulation hardware and concurrent electrophysiology with cloud-based algorithms to deliver individualized stimulation to targeted brain networks using an induction-plus-maintenance protocol. Intended for investigational use in clinical research.
Services
Design and conduct of randomized, double-blind, sham-controlled clinical studies of personalized noninvasive neuromodulation, including imaging and electrophysiology sub-studies, safety monitoring, and multi-center site coordination.
Structural, microstructural and connectivity MRI analyses and extraction of stimulation-evoked electrophysiology features to evaluate biological effects of neuromodulation interventions and support biomarker development.
Facilitation of development and supply collaborations with specialized stimulation, neuronavigation and electrophysiology hardware manufacturers to support clinical system development, trial deployment and scale-up to commercial production.
Support for establishing and managing public-private collaborations involving government, industry, academia, patient-advocacy and philanthropic organizations to advance research programs and consortia.
Advisory and implementation services to build or integrate secure, scalable research workbench platforms and data infrastructure to support multi-site studies and large-scale analyses.
Design and conduct of randomized, double-blind, sham-controlled clinical studies of personalized noninvasive neuromodulation, including imaging and electrophysiology sub-studies, safety monitoring, and multi-center site coordination.
Structural, microstructural and connectivity MRI analyses and extraction of stimulation-evoked electrophysiology features to evaluate biological effects of neuromodulation interventions and support biomarker development.
Facilitation of development and supply collaborations with specialized stimulation, neuronavigation and electrophysiology hardware manufacturers to support clinical system development, trial deployment and scale-up to commercial production.
Support for establishing and managing public-private collaborations involving government, industry, academia, patient-advocacy and philanthropic organizations to advance research programs and consortia.
Advisory and implementation services to build or integrate secure, scalable research workbench platforms and data infrastructure to support multi-site studies and large-scale analyses.
Expertise Areas
- Neuromodulation clinical development and trial operations
- Perturbation-based electrophysiology biomarker discovery (TMS-EEG)
- Multimodal neuroimaging and connectomics analysis (structural, diffusion, functional MRI)
- Machine learning for treatment personalization and longitudinal recalibration
Key Technologies
- Repetitive transcranial magnetic stimulation (rTMS)
- MRI-guided neuronavigation
- Concurrent stimulation and electrophysiology (TMS-EEG)
- High-density multi-channel EEG
News & Updates
Sinaptica Therapeutics received FDA breakthrough device designation for its electromagnetic therapy system for Alzheimer’s disease, marking a significant milestone in its development pathway.
A pilot study demonstrating that personalized rTMS-EEG therapy slowed brain atrophy and increased connectivity in Alzheimer’s patients, supporting the potential disease-modifying effects of the treatment.
An article discussing the potential of personalized rTMS to slow cognitive decline in Alzheimer’s disease, highlighting Sinaptica’s innovative approach and clinical trial results.
Overview of recent neurostimulation studies, including Sinaptica’s promising results in Alzheimer’s disease, emphasizing the emerging role of neuromodulation therapies.
Recognition by the FDA of the innovative potential of Sinaptica’s electromagnetic therapy system for Alzheimer’s disease.
Sinaptica Therapeutics received FDA breakthrough device designation for its electromagnetic therapy system for Alzheimer’s disease, marking a significant milestone in its development pathway.
A pilot study demonstrating that personalized rTMS-EEG therapy slowed brain atrophy and increased connectivity in Alzheimer’s patients, supporting the potential disease-modifying effects of the treatment.
An article discussing the potential of personalized rTMS to slow cognitive decline in Alzheimer’s disease, highlighting Sinaptica’s innovative approach and clinical trial results.
Overview of recent neurostimulation studies, including Sinaptica’s promising results in Alzheimer’s disease, emphasizing the emerging role of neuromodulation therapies.
Recognition by the FDA of the innovative potential of Sinaptica’s electromagnetic therapy system for Alzheimer’s disease.